Abstract
Objective. The cancer of the prostate risk assessment (CAPRA-S) postsurgical score predicts recurrence, metastasis, and cancer-specific survival after radical prostatectomy (RP). We evaluated the relation between CAPRA-S score and biochemical recurrence (BCR) in prostate cancer after RP in our clinic. Materials and Methods. This study was performed on 203 patients with prostate carcinoma who underwent open RP and regional lymph node dissection in our clinic between 2008 and 2013. We calculated the CAPRA-S scores including prostate-specific antigen (PSA) at diagnosis, pathology Gleason score, surgical margin, seminal vesicle invasion, extracapsular extension, and lymph node involvement. The patients were divided into 3 risk groups (low, intermediate, and high risk) according to risk scores. Results. Recurrence occurred in 17.8% of the patients (36 patients out of 203 patients) with a median of 11.7-month follow-up. The average recurrence-free survival time is 44.6 months. Surgical margin invasion and seminal vesicle invasion significantly correlated with BCR especially in high risk group (11 and 13 of 15 patients, p < 0.05, resp.). Conclusion. CAPRA-S score can be easily calculated and it is useful in clinical practice in order to timely propose adjuvant therapies after surgery.
Highlights
Prostate cancer is the most common noncutaneous malignancy
In 2005, UCSF (University California-San Francisco) proposed a nomogram known as Cancer of the Prostate Risk Assessment (CAPRA), a pretreatment score based on patient age, prostate-specific antigen (PSA), biopsy Gleason score, clinical stage, and percent of positive biopsy cores [5]
We showed the relationship between biochemical recurrence (BCR) and cancer of the prostate risk assessment (CAPRA-S) scores in Figures 1 and 2
Summary
Prostate cancer is the most common noncutaneous malignancy. In 2014, 233000 new cases were diagnosed and 29480 cancer-specific deaths were estimated [1]. In 2005, UCSF (University California-San Francisco) proposed a nomogram known as Cancer of the Prostate Risk Assessment (CAPRA), a pretreatment score based on patient age, PSA, biopsy Gleason score, clinical stage, and percent of positive biopsy cores [5]. Pathology findings like pathologic Gleason score, surgical margin, extracapsular extension, seminal vesicle invasion, and lymph node involvement were added to the new score system [6]. This new system is validated by various studies and confirmed BCR prediction [4, 7,8,9]. In this study we examine the validity of the CAPRA-S score in our institution
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have